Biotech firm faces challenges from FDA, falling stock prices.
Reynolds
Tom
T
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D007880:Legislation, Drug; D008402:Mass Media; D016032:Randomized Controlled Trials as Topic; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000068818:Cetuximab